How much did Stryker pay for Amplitude Vascular Systems?

The deal value was not disclosed in available sources. AVS had previously raised a $36M Series B round prior to the acquisition announcement on April 13, 2026.

How does this acquisition fit into Stryker's overall strategy?

It follows Stryker's $4.9B acquisition of Inari Medical (completed February 2025), reflecting a clear strategy to build a comprehensive peripheral vascular intervention franchise targeting both venous and arterial disease segments.

What is Intravascular Lithotripsy (IVL) and how is AVS's technology different?

IVL uses sonic pressure waves to fracture calcified plaque in arteries, enabling better vessel preparation. AVS's platform specifically uses pulsed CO₂-generated pressure waves, offering a differentiated delivery mechanism versus existing revascularization approaches.

Which competitor stocks could be affected by Stryker's vascular expansion?

Boston Scientific and Medtronic both compete in peripheral vascular intervention and face incremental competitive pressure as Stryker broadens its device portfolio in this segment.

快速链接

斯特瑞克收购幅度血管系统以增强下一代外周血管组合

发布时间: 2026-04-13 13:46:17 UTC

查看 SYK 页码

数据快照

Price

$341.35

24h Low

$339.50

24h High

$341.70

24h Change

+0.40%

24h Change (%)

+0.60%

SYK Current Price

$340.65

AVS Series B Funding

$36M

Prior SYK Acquisition (Inari Medical)

$4.9B

重点摘要

•Stryker signed a definitive agreement on April 13, 2026 to acquire Amplitude Vascular Systems, adding a novel CO₂-based IVL platform for calcified peripheral arterial disease treatment.
•The deal follows Stryker's $4.9B Inari Medical acquisition (Feb 2025), confirming a deliberate, accelerating strategy to build a comprehensive peripheral vascular portfolio.
•Deal financial terms were undisclosed; AVS had raised a $36M Series B — a successful medtech VC exit validating acquisition appetite for specialized innovators.
•Near-term SYK price impact is muted (trading at $340.65, +0.40%); long-term upside depends on regulatory clearance and commercial integration of AVS's IVL technology.
•Sector peers including Boston Scientific and Medtronic face incremental competitive pressure in the peripheral vascular segment as Stryker expands its procedural toolkit.

根据斯特瑞克通过GlobeNewswire发布的官方投资者关系新闻稿，斯特瑞克公司 (NYSE: SYK) 于2026年4月13日签署了一项最终协议，以收购幅度血管系统 (AVS)，这是一家总部位于波士顿的医疗科技初创公司，专注于下一代血管内碎石 (IVL) 技术。AVS的专有平台利用脉冲二氧化碳生成的压力波来治疗钙化的外周动脉疾病——与传统的再血管化疗法相比，这是一种差异化的方法。交易的财务条款

事件分析

根据斯特瑞克通过GlobeNewswire发布的官方投资者关系新闻稿，斯特瑞克公司 (NYSE: SYK) 于2026年4月13日签署了一项最终协议，以收购幅度血管系统 (AVS)，这是一家总部位于波士顿的医疗科技初创公司，专注于下一代血管内碎石 (IVL) 技术。AVS的专有平台利用脉冲二氧化碳生成的压力波来治疗钙化的外周动脉疾病——与传统的再血管化疗法相比，这是一种差异化的方法。交易的财务条款未披露；AVS在收购前曾进行过3600万美元的B轮融资。

这笔交易并非孤立的举动。它是在斯特瑞克于2025年2月完成49亿美元收购Inari Medical之后进行的，明确加速了其主导外周血管介入领域的战略。Inari处理静脉血栓栓塞，而AVS则填补钙化动脉疾病的空白——为斯特瑞克提供了更全面的血管手术工具包。其战略逻辑令人信服：外周动脉疾病（PAD）在全球影响数千万患者，而钙化病变仍然是最难治疗的子集之一，现有选项有限。

更广泛的意义在于这对医疗科技并购的信号。大型设备制造商越来越多地收购专注的私人创新者，而不是从零开始开发——压缩了创新到商业化的时间线。对于医疗保健行业而言，这验证了持续资本投向高增长血管市场的有效性，加强了对突破性医疗科技初创公司的收购溢价环境的支持。根据2026年股票市场展望，医疗保健并购仍然是今年行业阿尔法的结构性驱动因素。

这对交易者意味着什么

对于持有或关注斯特瑞克 (SYK)的交易者而言，此次收购是一个适度但积极的催化剂。以当前价格340.65美元（当天上涨0.40%，根据实时数据）来看，市场的反应较为温和，表明市场将此视为战略一致而非变革性——Inari交易设定了高标准。短期的上涨可能会受到限制，除非交易条款显示出有意义的技术溢价。更有意义的长期角度是，一旦IVL平台获得监管批准并在斯特瑞克的分销网络中实现商业规模，所带来的利润和收入贡献。

该交易为行业同行的观察名单创造了相关性。波士顿科学和美敦力公司都在外周血管介入领域竞争；斯特瑞克的投资组合扩张逐渐对他们的血管业务线施加压力。爱德华生命科学公司受到的影响较小，但仍然是更广泛的医疗科技情绪组合的一部分。State Street Health Care Select Sector SPDR ETF (XLV) 由于持续的行业并购动力，获得适度的好处，这表明对医疗保健创新需求的信心。

预计SYK的波动性将保持较低，除非出现监管时间表或整合问题。交易者应密切关注机构医疗基金是否利用公告后的跌势作为增持机会，因为斯特瑞克在并购中的执行记录一贯良好。标准普尔500指数的反应微不足道，鉴于SYK的权重，但医疗保健行业轮换仍然是值得跟踪的主题。

在CoinUnited.io上交易斯特瑞克公司

[以高达1000倍杠杆交易SYK `

创建免费账户

常见问题

AVS is a Boston-based medtech startup developing next-generation Intravascular Lithotripsy (IVL) technology using pulsed CO₂ pressure waves to treat calcified peripheral arterial disease. Stryker acquired it to expand its peripheral vascular portfolio with a differentiated therapy addressing a high unmet clinical need.